Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 6/20 | 0.32 |
| ▸ | HTR2C | P28335 | 6/20 | 0.32 |
| ▸ | HTR2B | P41595 | 6/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20939382 | 0.83 | HTR7 (0.47) | HTR7HTR1AMAP3K14HTR2AHTR2C | |
| SCHEMBL20939596 | 0.76 | MAP3K14 (0.39) | MAP3K14 | |
| SCHEMBL20939658 | 0.72 | HTR7 (0.58) | HTR7HTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL4107808 | 0.66 | PARP1 (0.39) | — | |
| SCHEMBL30695888 | 0.66 | PARP1 (0.39) | — | |
| SCHEMBL30786036 | 0.64 | HTR1A (0.42) | HTR7HTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL21142131 | 0.64 | HTR1A (0.42) | HTR7HTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL7332352 | 0.64 | NOTUM (0.38) | — | |
| SCHEMBL11462012 | 0.63 | DRD2 (0.50) | HTR7HTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL9787124 | 0.62 | HTR7 (0.58) | HTR7HTR1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-30 | — | — | US | disclosed |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | US | disclosed |
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, NFKBIA, MAP3K15 | HTR7 4709/4885HTR1A 4857/4885MAP3K14 1/4885 |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | HTR7 4576/4885HTR1A 4814/4885MAP3K14 6/4885 |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | HTR7 4709/4885HTR1A 4857/4885MAP3K14 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.